Curated News
By: NewsRamp Editorial Staff
September 11, 2025
Kairos Pharma to Reveal Prostate Cancer Drug Trial Results Sept 18
TLDR
- Kairos Pharma's ENV105 shows promise in overcoming cancer drug resistance, potentially giving patients and investors an edge with its novel combination therapy approach.
- ENV105 targets CD105 protein to reverse drug resistance, restoring effectiveness of standard cancer therapies through structural biology mechanisms in Phase 2 trials.
- This breakthrough therapy could significantly improve prostate cancer treatment outcomes and quality of life for patients facing drug-resistant disease progression.
- Kairos Pharma reveals interim Phase 2 results for ENV105, an antibody targeting cancer drug resistance through innovative CD105 protein inhibition technology.
Impact - Why it Matters
This development matters because prostate cancer remains one of the most common cancers in men worldwide, with advanced stages often developing resistance to existing treatments. The ENV105 compound represents a novel approach to overcoming treatment resistance, which could potentially extend survival and improve quality of life for patients facing limited options. Successful results from this trial could lead to new combination therapies that address the critical challenge of drug resistance in oncology, potentially benefiting not only prostate cancer patients but also those with other cancers where CD105-mediated resistance occurs.
Summary
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company based in Los Angeles, California, has announced it will host a key opinion leader event on September 18, 2025, at 5 p.m. ET to discuss interim efficacy results from its Phase 2 trial of lead candidate ENV105 in advanced prostate cancer. CEO Dr. John Yu emphasized that the event will showcase safety and efficacy findings from the ENV105 and apalutamide combination therapy, with expert perspectives highlighting the compound's potential role in addressing cancer drug resistance.
The company's innovative approach focuses on utilizing structural biology to overcome drug resistance and immune suppression in cancer. ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. The elevation of CD105 in response to standard therapy often results in resistance and disease relapse. ENV105 aims to reverse this drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs in oncology.
This news was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on biotechnology and life sciences developments. BioMedWire provides comprehensive distribution services including wire solutions, article syndication to over 5,000 outlets, press release enhancement, and social media distribution to millions of followers, ensuring maximum reach and impact for companies like Kairos Pharma in the competitive biopharmaceutical landscape.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma to Reveal Prostate Cancer Drug Trial Results Sept 18
